RUA vs. BELL, POLX, IHC, AVO, MHC, SUN, DEMG, SN, MXCT, and NIOX
Should you be buying RUA Life Sciences stock or one of its competitors? The main competitors of RUA Life Sciences include Belluscura (BELL), Polarean Imaging (POLX), Inspiration Healthcare Group (IHC), Advanced Oncotherapy (AVO), MyHealthChecked (MHC), Surgical Innovations Group (SUN), Deltex Medical Group (DEMG), Smith & Nephew (SN), MaxCyte (MXCT), and NIOX Group (NIOX). These companies are all part of the "medical devices" industry.
RUA Life Sciences vs.
Belluscura (LON:BELL) and RUA Life Sciences (LON:RUA) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their community ranking, media sentiment, earnings, dividends, valuation, institutional ownership, profitability, risk and analyst recommendations.
Belluscura has a beta of 1.05, meaning that its share price is 5% more volatile than the S&P 500. Comparatively, RUA Life Sciences has a beta of 1.21, meaning that its share price is 21% more volatile than the S&P 500.
RUA Life Sciences has higher revenue and earnings than Belluscura. RUA Life Sciences is trading at a lower price-to-earnings ratio than Belluscura, indicating that it is currently the more affordable of the two stocks.
Belluscura and RUA Life Sciences both received 0 outperform votes by MarketBeat users.
Belluscura has a net margin of 0.00% compared to RUA Life Sciences' net margin of -65.72%. RUA Life Sciences' return on equity of -24.27% beat Belluscura's return on equity.
In the previous week, Belluscura's average media sentiment score of 0.00 equaled RUA Life Sciences'average media sentiment score.
6.3% of Belluscura shares are owned by institutional investors. Comparatively, 26.0% of RUA Life Sciences shares are owned by institutional investors. 56.3% of Belluscura shares are owned by insiders. Comparatively, 51.3% of RUA Life Sciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Summary
RUA Life Sciences beats Belluscura on 7 of the 11 factors compared between the two stocks.
Get RUA Life Sciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for RUA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
RUA Life Sciences Competitors List
Related Companies and Tools
This page (LON:RUA) was last updated on 1/22/2025 by MarketBeat.com Staff
Free RUA Stock Alerts